See more : COSCO SHIPPING Energy Transportation Co., Ltd. (CSDXF) Income Statement Analysis – Financial Results
Complete financial analysis of Impel Pharmaceuticals Inc. (IMPL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Impel Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- QuantumScape Corporation (QS) Income Statement Analysis – Financial Results
- CHANGJIU HLDGS (6959.HK) Income Statement Analysis – Financial Results
- Tarsus Pharmaceuticals, Inc. (TARS) Income Statement Analysis – Financial Results
- Amdocs Limited (DOX) Income Statement Analysis – Financial Results
- Osotspa Public Company Limited (OSP-R.BK) Income Statement Analysis – Financial Results
Impel Pharmaceuticals Inc. (IMPL)
About Impel Pharmaceuticals Inc.
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 12.65M | 668.00K | 0.00 | 0.00 |
| Cost of Revenue | 6.50M | 691.00K | 0.00 | 0.00 |
| Gross Profit | 6.16M | -23.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 48.66% | -3.44% | 0.00% | 0.00% |
| Research & Development | 11.46M | 20.56M | 27.29M | 28.81M |
| General & Administrative | 77.89M | 50.90M | 18.05M | 12.75M |
| Selling & Marketing | 7.60M | 12.60M | 0.00 | 0.00 |
| SG&A | 77.89M | 50.90M | 18.05M | 12.75M |
| Other Expenses | -9.29M | -5.05M | -408.00K | -680.00K |
| Operating Expenses | 89.34M | 71.46M | 45.33M | 41.57M |
| Cost & Expenses | 95.84M | 72.15M | 45.33M | 41.57M |
| Interest Income | 10.58M | 2.25M | 0.00 | 417.00K |
| Interest Expense | 13.84M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.20M | 1.09M | 1.08M | 722.00K |
| EBITDA | -83.18M | -70.40M | -44.26M | -40.84M |
| EBITDA Ratio | -657.48% | -10,701.50% | 0.00% | 0.00% |
| Operating Income | -83.18M | -71.49M | -45.33M | -41.57M |
| Operating Income Ratio | -657.48% | -10,701.50% | 0.00% | 0.00% |
| Total Other Income/Expenses | -23.13M | -5.05M | -463.00K | -263.00K |
| Income Before Tax | -106.31M | -76.53M | -45.80M | -41.83M |
| Income Before Tax Ratio | -840.28% | -11,457.19% | 0.00% | 0.00% |
| Income Tax Expense | 23.13M | 2.00K | 1.00K | 30.00K |
| Net Income | -129.44M | -76.54M | -45.80M | -41.86M |
| Net Income Ratio | -1,023.08% | -11,457.49% | 0.00% | 0.00% |
| EPS | -5.52 | -5.24 | -3.49 | -3.19 |
| EPS Diluted | -5.52 | -5.24 | -3.49 | -3.19 |
| Weighted Avg Shares Out | 23.45M | 14.60M | 13.14M | 13.14M |
| Weighted Avg Shares Out (Dil) | 23.45M | 14.60M | 13.14M | 13.14M |
Why Impel NeuroPharma Gained 17% Today Then Faded
Impel NeuroPharma Announces Launch of Proposed Public Offering
Impel (IMPL) Gets FDA Nod for Trudhesa in Migraine Treatment
This analyst raised his price target on Impel NeuroPharma by more than 50%
Cowen Beefs Up Target Price For This Medical Device Firm
IMPL Stock: Over 10% Increase Explanation
Why Impel NeuroPharma Stock Is Soaring Today
FDA Gives Nod To Nasal Spray Migraine Treatment From Impel NeuroPharma; Stock Jumps
Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine
Source: https://incomestatements.info
Category: Stock Reports